Searched for
THYROCARE NEWS
Peak XV rejigs Surge; Digital lenders power through slowdownHappy Monday! Peak XV Partners is rebooting Surge after executive exits and a broader strategy reset. This and more in today’s ETtech Morni...- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the latest news flow from the Gulf region, the probability is high that we might once again see the bulls attempting a comeback. As u...
- Earnings are strong, but margin pain is coming; Dharmesh Kant on 3 sectors worth owning nowIndian corporate profits are currently strong. However, rising input costs present a significant challenge ahead. Investors should remain p...
- JioBlackRock Flexi Cap Fund exits Swiggy, 20 other stocks; adds ICICI Pru AMC and 9 more in MarchJioBlackRock Mutual Fund’s Flexi Cap Fund exited Swiggy and 20 other stocks in March, while adding ICICI Prudential Asset Management Compan...
- Thyrocare Technologies' shares down 67%? Here's why investors shouldn't worryThyrocare Technologies’ shares slumped 66.7% to ₹492 on Friday as they began trading ex-bonus for the recently announced 2:1 bonus issue. T...
- 'Rs 43.5 LPA for NIT topper and then suddenly laid off': Thyrocare founder's warning to young professionalsAn NIT topper's layoff from a high-paying job sparked concern, prompting Thyrocare founder Dr. Velumani to warn graduates about deceptive c...
- Wondering how to succeed and build wealth? Rs 5,000 crore man shares his secret to true successA Bengaluru resident shared concerns about financial instability despite a high income. Dr. A Velumani, founder of Thyrocare, responded emp...
- Buy Thyrocare Technologies, target price Rs 725: ICICI SecuritiesThyrocare Technologies Ltd. key Products/Revenue Segments include Diagnostics, Other Operating Revenue, Traded Goods for the year ending 31...
- Buy Thyrocare Technologies, target price Rs 725: ICICI SecuritiesThyrocare Technologies Ltd. key Products/Revenue Segments include Diagnostics, Other Operating Revenue, Traded Goods for the year ending 31...
- Buy Thyrocare Technologies, target price Rs 740: ICICI SecuritiesThyrocare Technologies Ltd., incorporated in the year 2000, is a Mid Cap company (having a market cap of Rs 3362.49 Crore) operating in Hos...
- Buy Thyrocare Technologies, target price Rs 740: ICICI SecuritiesThyrocare Technologies Ltd., incorporated in the year 2000, is a Mid Cap company (having a market cap of Rs 3228.73 Crore) operating in Hos...
- MSCI Rejig: 14 stocks including Fusion Micro, IRCON Intl enter Global Smallcap index; 9 exitMSCI Inc has announced changes to its Global Smallcap index, where 14 Indian stocks will enter while nine will exit the index on May 31. Th...
- Thyrocare Tech jumps 10%, crosses 100-DMA first time since Nov 2021At 12.35 pm, the scrip was trading 8.16 per cent higher at Rs 711 over the last day’s closing of Rs 657.35 a piece. The stock has declined ...
- Buy Thyrocare Technologies, target price Rs 980: ICICI SecuritiesThyrocare Technologies Ltd., incorporated in the year 2000, is a Mid Cap company (having a market cap of Rs 3513.57 Crore) operating in Hos...
- Buy Thyrocare Technologies, target price Rs 1300: Yes SecuritiesThyrocare Technologies Ltd., incorporated in the year 2000, is a Mid Cap company (having a market cap of Rs 6215.12 Crore) operating in Hos...
- PharmEasy to acquire 66% stake in Thyrocare Tech, to make open offer to grab additional 26%PharmEasy claims to be India’s number one online pharmacy and diagnostics brand. Thyrocare prides itself as the largest diagnostic company.
- Travel companies rally, lab & food hitThe news about a potent vaccine from global pharma giant Pfizer, along with Germany’s BioNTech, was a booster for hotel, airline and travel...
- Diagnostic cos fall on Reliance Life’s proposed entryOn Monday, these three stocks fell between 1 per cent and 3 per cent.
- Leaders of Tomorrow kick-starts with Whitney Johnson & Brand CapitalEntrepreneurship is gathering momentum in India. Ambitious entrepreneurs are bringing in innovations and disrupting the Indian market. Lead...
- Dr Lal PathLabs: Sweet pill in Dec quarter, expansion key to future growthThe main concern should be the company’s excessive concentration on the North market.
Load More
